作者
Alexandra C Walls, Brooke Fiala, Alexandra Schäfer, Samuel Wrenn, Minh N Pham, Michael Murphy, V Tse Longping, Laila Shehata, Megan A O’Connor, Chengbo Chen, Mary Jane Navarro, Marcos C Miranda, Deleah Pettie, Rashmi Ravichandran, John C Kraft, Cassandra Ogohara, Anne Palser, Sara Chalk, E-Chiang Lee, Kathryn Guerriero, Elizabeth Kepl, Cameron M Chow, Claire Sydeman, Edgar A Hodge, Brieann Brown, Jim T Fuller, Kenneth H Dinnon, Lisa E Gralinski, Sarah R Leist, Kendra L Gully, Thomas B Lewis, Miklos Guttman, Helen Y Chu, Kelly K Lee, Deborah H Fuller, Ralph S Baric, Paul Kellam, Lauren Carter, Marion Pepper, Timothy P Sheahan, David Veesler, Neil P King
发表日期
2020/11/25
期刊
Cell
卷号
183
期号
5
页码范围
1367-1382. e17
出版商
Elsevier
简介
A safe, effective, and scalable vaccine is needed to halt the ongoing SARS-CoV-2 pandemic. We describe the structure-based design of self-assembling protein nanoparticle immunogens that elicit potent and protective antibody responses against SARS-CoV-2 in mice. The nanoparticle vaccines display 60 SARS-CoV-2 spike receptor-binding domains (RBDs) in a highly immunogenic array and induce neutralizing antibody titers 10-fold higher than the prefusion-stabilized spike despite a 5-fold lower dose. Antibodies elicited by the RBD nanoparticles target multiple distinct epitopes, suggesting they may not be easily susceptible to escape mutations, and exhibit a lower binding:neutralizing ratio than convalescent human sera, which may minimize the risk of vaccine-associated enhanced respiratory disease. The high yield and stability of the assembled nanoparticles suggest that manufacture of the nanoparticle …
引用总数